Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Targeting Spliced X-Box Binding Protein 1 in Alternatively Activated Macrophages to prevent progression of lung fibrosis

EF 2018-19

Résumé
Fibroproliferative diseases, or diseases involving organ scarring and hardening, are associated with approximately 45% of deaths worldwide. Idiopathic Pulmonary Fibrosis (IPF) is a lung disease of unknown cause that leads to excessive scarring of the lungs. This causes compromised uptake of oxygen and decreased lung function. The median survival of patients with IPF after diagnosis is 2.5 to 3.5 years. Despite this short amount of time, this disease is poorly understood and there are limited treatment options. Therefore, it is important to better understand what causes this disease, and what can be done to investigate additional therapies. Endoplasmic reticulum (ER) stress has been shown to play a role in fibrotic disease. The ER is a part of the cell where proteins are made and folded, and is also the quality control centre to ensure that proteins are folded correctly. When ER stress occurs, causing a build-up of unfolded or misfolded proteins, the unfolded protein response (UPR) is activated, which aims to help fix or destroy the faulty proteins. There are three main pathways of the UPR, and the one being investigated here is called the inositol-requiring enzyme 1 (IRE1) pathway. When IRE1 is activated, a protein called spliced x-box protein 1 (XBP1) is present. The IRE1 pathway and spliced XBP1 will be explored to determine if they play a key role in IPF, and if blocking this pathway can help to prevent the worsening of the disease. Inhibitors, or blockers, of the IRE1 pathway will be given to mouse models of pulmonary fibrosis, and the levels of spliced XBP1 as well as effects on fibrosis will then be studied through various techniques. The results of this study will help to determine if targeting this pathway could be a potential route of treatment for IPF.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
406428
Name
Vierhout Megan J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting Spliced X-Box Binding Protein 1 in Alternatively Activated Macrophages to prevent progression of lung fibrosis
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alternatively Activated Macrophages; Endoplasmic Reticulum Stress; Idiopathic Pulmonary Fibrosis; Inositol Requiring Enzyme 1; Ire1 Inhibition; Spliced X-Box Binding Protein 1; Target Identification; Unfolded Protein Response
Abstract
Fibroproliferative diseases, or diseases involving organ scarring and hardening, are associated with approximately 45% of deaths worldwide. Idiopathic Pulmonary Fibrosis (IPF) is a lung disease of unknown cause that leads to excessive scarring of the lungs. This causes compromised uptake of oxygen and decreased lung function. The median survival of patients with IPF after diagnosis is 2.5 to 3.5 years. Despite this short amount of time, this disease is poorly understood and there are limited treatment options. Therefore, it is important to better understand what causes this disease, and what can be done to investigate additional therapies. Endoplasmic reticulum (ER) stress has been shown to play a role in fibrotic disease. The ER is a part of the cell where proteins are made and folded, and is also the quality control centre to ensure that proteins are folded correctly. When ER stress occurs, causing a build-up of unfolded or misfolded proteins, the unfolded protein response (UPR) is activated, which aims to help fix or destroy the faulty proteins. There are three main pathways of the UPR, and the one being investigated here is called the inositol-requiring enzyme 1 (IRE1) pathway. When IRE1 is activated, a protein called spliced x-box protein 1 (XBP1) is present. The IRE1 pathway and spliced XBP1 will be explored to determine if they play a key role in IPF, and if blocking this pathway can help to prevent the worsening of the disease. Inhibitors, or blockers, of the IRE1 pathway will be given to mouse models of pulmonary fibrosis, and the levels of spliced XBP1 as well as effects on fibrosis will then be studied through various techniques. The results of this study will help to determine if targeting this pathway could be a potential route of treatment for IPF.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vierhout, Megan J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~